Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 116,936	$ 97,421	$ 343,030	$ 228,191
General and administrative	22,988	15,605	64,347	43,174
Total operating expenses	139,924	113,026	407,377	271,365
Loss from operations	(139,924)	(113,026)	(407,377)	(271,365)
Other income, net:
Interest income	28,057	18,495	73,536	45,339
Grant income	292	1,640	812	4,759
Realized gains on marketable securities	1	0	50	0
Foreign currency transaction gains (losses)	8,450	227	6,132	(198)
Total other income, net	36,800	20,362	80,530	49,900
Net loss	$ (103,124)	$ (92,664)	$ (326,847)	$ (221,465)
Net loss per share, basic (in dollars per share)	$ (0.83)	$ (0.91)	$ (2.78)	$ (2.32)
Net loss per share, diluted (in dollars per share)	$ (0.83)	$ (0.91)	$ (2.78)	$ (2.32)
Weighted-average shares outstanding, basic (in shares)	123,693,461	101,668,655	117,596,424	95,367,751
Weighted-average shares outstanding, diluted (in shares)	123,693,461	101,668,655	117,596,424	95,367,751